|Drug class||platelet-derived growth factor.|
|Main uses||Diabetic foot ulcer due to neuropathy|
|Side effects||Red rash|
Becaplermin, sold under the brand name Regranex, is a medication used for diabetic foot ulcer of the leg due to neuropathy. It is only used in cases that have sufficient blood supply. It is applied to the skin.
Becaplermin was approved for medical use in the United States in 1997. While it was approved for use in Europe in 1999, this approval was subsequently withdrawn. It was refused approval for gum tissue loss in Europe in 2009. In the United States it costs about 1,200 USD for a 15 gram tube as of 2022.
The drug is used for the treatment of diabetic foot ulcers. Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster. Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.
The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator. Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. 
A boxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used. Regranex should be used with caution in patients with known malignancy.
- "DailyMed - REGRANEX- becaplermin gel". dailymed.nlm.nih.gov. Archived from the original on 24 March 2021. Retrieved 8 January 2022.
- "Becaplermin Monograph for Professionals". Drugs.com. Retrieved 8 January 2022.
- "Regranex". Archived from the original on 11 January 2022. Retrieved 8 January 2022.
- "Gemesis". Archived from the original on 5 April 2021. Retrieved 8 January 2022.
- "Becaplermin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 8 January 2022.
- Nagai MK, Embil JM (February 2002). "Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers". Expert Opinion on Biological Therapy. 2 (2): 211–8. doi:10.1517/147125184.108.40.206. PMID 11849120. S2CID 28408255.
- Wieman TJ, Smiell JM, Su Y (May 1998). "Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study". Diabetes Care. 21 (5): 822–7. doi:10.2337/diacare.21.5.822. PMID 9589248. S2CID 20595962.
- Persson U, Willis M, Odegaard K, Apelqvist J (2000). "The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data". Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 3 Suppl 1: 39–46. doi:10.1046/j.1524-4733.2000.36027.x. PMID 16464208.
- "REGRANEX Gel Highlights of Prescribing Information" (PDF). Smith & Nephew, Inc. Archived from the original (PDF) on 26 August 2016.
- Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
- FDA Professional Drug Information for Regranex.
- Waknine Y (9 June 2008). "Diabetic Ulcer Gel Gets Black Box Warning". Medscape. Archived from the original on 24 June 2019. Retrieved 14 October 2021.